Objective: Mitotane is used for the treatment of adrenocortical carcinoma. High oral daily doses of typically 1-6 g are required to attain therapeutic concentrations. The drug has a narrow therapeutic index and patient management is difficult because of a high volume of distribution, very long elimination half-life, and drug interaction through induction of metabolizing enzymes. The present evaluation aimed at the development of a population pharmacokinetic model of mitotane to facilitate therapeutic drug monitoring.
Introduction
The adrenolytic drug mitotane (1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl) ethyl] benzene) is the only approved treatment of the orphan malignant disease adrenocortical carcinoma (ACC). ACC has a high rate of recurrence after complete tumor resection and a dismal prognosis in advanced stages (1, 2). Mitotane is used both as an adjuvant treatment after complete tumor resection (3, 4) and for palliative treatment of advanced disease (5). Clinically used drug effects of mitotane include reduction of tumor related steroid hormone excess and a direct cytotoxic effect leading to objective treatment response in ~20% of cases (6) which appears to be relatively specific to cells of the adrenal cortex. Several molecular mechanisms for mitotane action appear to contribute to mitotane efficacy (7, 8, 9). We recently found sterol-O-acyl transferase 1 to be inhibited by mitotane which leads to impaired steroidogenesis and lipid induced endoplasmic reticulum stress (10). Published data on the pharmacokinetics of mitotane are scarce and have been conducted in small patient series only. It has been shown that mitotane has a low oral bioavailability (F) of 35-40% (11) and a high volume of distribution which is likely due to its lipophilic nature and extensive accumulation in adipose tissue (12). The majority of mitotane has been found to be bound to lipoprotein particles in circulation with pharmacological activity limited to the unbound fraction (13, 14, 15).
Efficacy of mitotane treatment is associated with plasma concentrations >14 mg/l which could be demonstrated in several retrospective series both in adjuvant and palliative treatment with mitotane monotherapy (6, 16, 17, 18, 19, 20) but also in combination with cytotoxic drugs in advanced disease (21, 22) . Adverse effects, including CNS toxicity are associated with plasma concentrations exceeding 20 mg/L (23). However, the time interval to achieve therapeutic plasma concentrations of mitotane limits the clinical utility of the drug regardless of the dosing regimen applied (24, 25, 26) . Accordingly, therapeutic drug monitoring (TDM) is needed for continuous treatment evaluation and decision making. There is a poor correlation of mitotane dose with plasma concentrations, which suggests the involvement of other factors influencing the attainment of therapeutic concentrations (27).
Main metabolites of mitotane are o,p′-dichlorodiphenyl-ethene (o,p'-DDE) and -acetate (o,p'-DDA) (28, 29) . o,p'-DDA can be detected at ten-fold higher concentration in blood than mitotane itself whereas o,p'-DDE is barely detectable in most cases (19, 30) . Small amounts of these derivatives apparently undergo aromatic hydroxylation and glycine conjugation (28). The compound is a strong inducer of hepatic CYP3A4 in vitro and in vivo, which causes interactions with co-administered drugs such as sunitinib (31, 32, 33, 34) . Orally administered mitotane is excreted in urine and bile and has a long elimination half-life ranging from 18-159 days (35).
In vitro, drug metabolizing enzymes and transporters beyond CYP3A4 were induced by mitotane, probably via the pregnane X receptor (PXR) (32). PXR ligands transcriptionally induce the activity of a broad range of processes in drug metabolism, which in turn often also accelerate the metabolism of PXR ligands, a phenomenon called autoinduction (36, 37). It is therefore conceivable that mitotane metabolism may be affected by autoinduction, and variability in autoinduction may contribute to differences in clinical toxicity and efficacy among patients. Thus, it might be helpful to account for enzyme induction in order to appropriately describe the pharmacokinetics of mitotane during a long-term treatment. A quantitative description of enzyme induction by mitotane in patients may also be useful to predict drug interactions that may limit the exposure to coadministered chemotherapeutic or targeted agents (3). Previous modeling efforts have not considered autoinduction (38).
The objective of the present evaluation is thus to develop a model describing mitotane pharmacokinetics incorporating enzyme autoinduction, which should contribute to optimizing mitotane dosing schedules.
Subjects and methods

Patients characteristics and data preparation
Clinical and demographical data were retrieved from records of patients participating in the German ACC Registry and the European Network for the Study of Adrenal Tumors (ENSAT) at a single reference center. Both registries have been approved by the ethics committee of the University of Würzburg (approval number 86/03 and 88/11) and all patients provided written informed consent to participate in the study. The following parameters were collected: age, sex, weight, height, body mass index, ENSAT tumor stage, treatment intention, concomitant systemic therapy, albumin, triglyceride, high and low-density lipoprotein, cholesterol, creatinine, and γ-glutamyltransferase (γ-GT) plasma concentrations. Mitotane plasma concentrations were measured within the Lysosafe® TDM provided on behalf of the manufacturer, HRA-Pharma (Paris, France) using HPLC.
A total number of 103 patients with adrenocortical carcinoma were treated with oral mitotane doses (0.5-10g per day, with interruptions). R (version 3.2.3) with 'dyplyr', 'tidyr' 'lubridate' and 'ggplot2' packages was used for data manipulation, cleaning and visualization (39, 40, 41, 42). All patients treated with mitotane over the age of 18 were eligible. Only patients with missing dosing at the initiation of therapy were excluded from analysis. Data from patients with missing dosing information during the treatment course was excluded partly by evaluating only data gathered during the period prior up to the missing information. Exploratory data analysis was performed to judge general trends in the data.
Data analysis and pharmacokinetic model development
Nonlinear mixed effect modeling was performed for data analysis. Estimation of pharmacokinetic parameters was performed by first order conditional estimation with interaction (FOCE-I) using NONMEM 7.4.1 (ICON, Development Solutions, Elliot City, MD, USA) (43) . Model development was aided by Pearl-speaks-NONMEM toolkit (Version 4.7.0) (44) . Graphical user interface Pirana (Version 2.9.6) was used for model management and execution, output generation and interpretation of results (45) . Xpose4 package with R was used for visualizing output data, post processing and analyzing NONMEM output (46) .
A compartmental approach was adapted in a stepwise manner to develop a pharmacokinetic model. In the first step, pharmacokinetic parameters representing a typical individual of the population were estimated using the basic structural model, followed by estimation of interindividual variability (IIV). Subsequently, a hypothetical mitotane metabolizing enzyme compartment was introduced.
Change in amount of drug in the central compartment ‫ܣ(‬ ‫ݐ݊݁ܿ,ܦ‬ ) was described by equation 1.
Where,
݇ܽ is the absorption rate constant, ‫ܣ‬ ‫ݐݑ݃,ܦ‬ is the amount of drug in gut compartment, ‫ܥ‬ ‫‬ is the mitotane plasma concentration, ‫ܮܥ‬ ‫݈݁݊݅݁ݏܾܽ‬ is the baseline mitotane clearance, ‫ܣ‬ ‫ݖ݊݁‬ is the relative amount of enzyme in hypothetical enzyme compartment.
Mitotane plasma concentrations influenced enzyme turnover rate and enhanced enzyme synthesis as described in equation 2.
The enzyme induction model assumes that the rate of enzyme synthesis ‫ܭ(‬ ݅݊ ) follows zero-order kinetics, while the rate of degradation ( ‫ܭ‬ ‫ݐݑ‬ ) follows first-order kinetics dependent upon relative amount of enzyme.
At steady state enzyme concentrations,
Parameters which could not be estimated from the data because of insufficient information were fixed according to published values or to arbitrary and/or physiologically plausible values which were subsequently evaluated by sensitivity analysis.
Other models tested included: (i) a two-compartment model; (ii) models with mitotane being eliminated by two distinct inducible and uninducible pathways; and (iii) models incorporating both gut wall and hepatic enzyme induction. A more complex
physiologically based approach was also tested including (iv) a minimal physiologically based pharmacokinetic model (47) ; and (v) a semiphysiological well stirred liver model to incorporate the first pass effect (48) . Both linear and nonlinear relationships (E max and sigmoidal E max models) were tested to describe the effect of mitotane on enzyme formation.
IIV was introduced to volumes of distribution and slope (Equation 4) assuming a normal distribution of ߟ with mean zero and variance ߱ 2 .
Where ߶ ݅,݆ is the jth individual pharmacokinetic parameter of the ith subject, ߠ ݆ the population estimate of the respective pharmacokinetic parameter and ߟ ݅,݆ the deviation of the subject's individual parameter from the population point estimate.
Additive, proportional and combined error models were scrutinized to obtain estimates for residual unexplained variability (RUV). For nested (hierarchical) models, the likelihood ratio test was used which assumes that the difference in objective function values (OFV) (representating an overall prediction error) between two models is chi- 
Covariate analysis
After successful development of a basic structural model, covariates were analyzed to provide an explanation for IIV and to improve overall model performance. Covariate preselection was based primarily on physiological plausibility. Graphical screening for potential covariates was performed including CWRES and individual pharmacokinetic parameters estimates versus covariates. Correlated covariates were avoided to be tested together and preference among those was given to the covariate with greater scientific plausibility if they provided a similar improvement of the model. Mitotane is reported to alter γ-GT (49) and triglyceride levels in patients and it is suggested to closely monitor the lipid profile during mitotane treatment (50) . As the drug is known to be accumulated in the adipose tissue, greater body fat proportion in women might have an impact influence upon its volume of distribution (51). Considering these facts, parameter covariate relationships were tested on volume of distribution (BMI and sex) and Slope (CL CR , plasma γ-GT and triglyceride levels).
Categorical covariate relationship (sex) was tested as a fractional change (θCOV) from the typical value of a parameter estimate (θ1)
Whereas, continuous covariates (BMI, CL CR , plasma γ-GT and triglyceride levels) were analyzed as linear relationships,
Final covariate inclusion in the model was mainly based upon the decrease in OFV and IIV.
Simulation study
Relative change in clearance over time was evaluated graphically by designing stochastic simulations with model estimates. Both high dose (day1: 1.5 g, day2: 3g, day3: 4.5g, day4-onwards: 6g daily) and low dose (day1-2: 1g, day3-5: 1.5g, day6-8: 2g, day 9-11:
2.5g, day12-onwards: 3g daily) regimens used in clinical practice (24, 25) were tested in simulated population over a period of 3 months. Statistical and graphical evaluation was performed with the aim to attain therapeutic mitotane concentrations (14-20mg/L), avoiding toxic concentrations and to define appropriate timing of first TDM.
Results
Data regarding 76 patients out of 103, 45 females and 31 males, could finally be included in the model development process. These patients were aged between 17 and 75 years, the body weight was between 44 and 129 kg. 1137 observations of concentration data were part of the analysis. Descriptive statistics of patient, disease and treatment characteristics are presented in Table 1 .
Absorption from gut compartment was modeled as a first order process. A onecompartment model was given preference over a two-compartment model, apparently because there was not sufficient information available in the data to precisely estimate peripheral volume of distribution and intercompartmental clearance. Although an empirical two-compartment model provided a lower OFV, this was at the expense of highly imprecise parameter estimates for volume of distribution and intercompartmental clearance. Attempt to fix these parameters according to published fat to plasma concentration ratios (12) resulted in even a higher IIV with regard to central volume of distribution and therefore conflicted with the model selection criteria. Fig. 1 
Discussion
In this by far largest and well characterized series of ACC patients on mitotane treatment, we investigate the pharmacokinetics of mitotane by implementing a nonlinear mixed effect modeling approach. The approach not only considers the fixed effects (descriptors of a process e.g., pharmacokinetic parameters and respective covariates) but also estimates the random variability (reflected by IIV and RUV) across the population by making use of nonlinear regression techniques. Mitotane showed a large and highly variable volume of distribution, partly explained by interindividual differences in BMI. The limitations of the evaluation related to retrospective nature of the present study suggest to design a prospective study for a more physiological and a more detailed description of mitotane pharmacokinetics. It would be desirable to (i) take more samples (e.g., 1 per day) during the initial build-up of plasma concentration; (ii) occasionally apply a dense sampling scheme including several samples within the first hour after dose during one dosing interval to describe mitotane absorption kinetics; (iii) evaluate the effect of additional covariates such as food intake, disease state and co-medications on mitotane pharmacokinetics, and (iv) to quantify enzyme induction during therapy by separate CYP3A probe drugs such as midazolam.
Conclusion
The proposed model appropriately describes plasma concentrations during chronic treatment with mitotane. It includes concentration dependent induction of metabolizing enzymes that considerably accelerates mitotane elimination. If tolerated, using the high dose regimen with a first TDM on day 16 of treatment might be a good treatment strategy. The model is a next important step to use pharmacokinetic modeling to improve personalized dose selection as well as establishing the timing of TDM, while more data are urgently needed.
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